Clinical Trial VICCNCPED1225

Title

PHIII Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects with Immune Thrombocytopenia (ITP)

Principal Investigator(s)

Richard Ho

Details

  • Protocol No. VICCNCPED1225
  • Open Date: 05/24/2012
  • Staging: Phase III
  • Age Group: Children
  • Scope: National
  • Objective: To evaluate the efficacy of romiplostim in the treatment of thrombocytopenia in pediatric subjects with ITP as measured by durable platelet response
  • Disease Sites:
  • Therapies: Correlative
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01444417
  • Secondary Protocol No: 20080279

Description

Eligibility

Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.